Currently available drugs for Chagas' disease are limited by toxicity and low efficacy in the chronic stage. Posaconazole, the most advanced new anti-chagasic drug candidate, did not fully confirm its initial potential in a Phase II clinical trial for chronic Chagas' disease. Given that posaconazole is highly active against Trypanosoma cruzi in vitro, and was very well tolerated in clinical trials, it should not be abandoned. Rather, a combination therapy may provide a highly promising outlook. Systems-scale approaches facilitate the hunt for a combination partner for posaconazole, which acts by blocking sterol biosynthesis. Mounting evidence suggests the functional interactions between sterols and sphingolipids in vivo. Here, we propose combining sterol and sphingolipid biosynthesis inhibitors to advance drug development in Chagas' disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pt.2014.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunomodulatory activity of Trypanosoma cruzi recombinant antigen combination TSA-1-C4 and Tc24-C4 induce activation of macrophages and CD8 T cells.
Parasitol Res
January 2025
Facultad de Química, Universidad Autónoma de Yucatán (UADY), Calle 43 S/N entre calle 96 y calle 40 Colonia Inalámbrica, Mérida, Yucatán, C.P. 97069, Mexico.
Chagas disease is a chronic infection caused by the protozoan parasite, Trypanosoma cruzi, with limited benefits of the currently available anti-parasitic chemotherapeutic approaches to halt the progression of heart disease. Recombinant TSA-1-C4 and Tc24-C4 proteins have been developed as promising antigen candidates for therapeutic vaccines, leading to propose them in combination as a bivalent recombinant protein strategy. In this study, we evaluated the immunomodulatory effect of the combined TSA-1-C4 and Tc24-C4 recombinant proteins by in vitro assays using murine macrophages.
View Article and Find Full Text PDFACCREDIT: Validation of clinical score for progression of COVID-19 while hospitalized.
Glob Epidemiol
June 2025
Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Brazil.
Unlabelled: COVID-19 is no longer a global health emergency, but it remains challenging to predict its prognosis.
Objective: To develop and validate an instrument to predict COVID-19 progression for critically ill hospitalized patients in a Brazilian population.
Methodology: Observational study with retrospective follow-up.
Factors influencing the use of direct oral anticoagulants among patients with chronic chagas cardiomyopathy.
Arch Peru Cardiol Cir Cardiovasc
December 2024
Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Heart Failure and Heart Transplant Clinic Fundación Cardiovascular de Colombia Floridablanca Colombia.
Objective: Chronic Chagas Cardiomyopathy (CCC) carries a high risk of embolic events due to structural changes in the left ventricle and frequent conduction disorders. However, there is limited data on anticoagulant prescription patterns and factors influencing the use of direct oral anticoagulants (DOACs) in these patients. This study aims to characterize CCC patients based on the anticoagulant therapy received and identify factors associated with DOACs use.
View Article and Find Full Text PDFFunctional heterogeneity of mesenchymal stem cells and their therapeutic potential in the K18-hACE2 mouse model of SARS-CoV-2 infection.
Stem Cell Res Ther
January 2025
Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Background: Despite many years of investigation into mesenchymal stem cells (MSCs) and their potential for treating inflammatory conditions such as COVID-19, clinical outcomes remain variable due to factors like donor variability, different tissue sources, and diversity within MSC populations. Variations in MSCs' secretory and proliferation profiles, and their proteomic and transcriptional characteristics significantly influence their therapeutic potency, highlighting the need for enhanced characterization methods to better predict their efficacy. This study aimed to evaluate the biological characteristics of MSCs from different tissue origins, selecting the most promising line for further validation in a K18-hACE2 mouse model of SARS-CoV-2 infection.
View Article and Find Full Text PDFEffects of the physical form of starter feed on the intake, performance, and health of female Holstein calves.
Animal
December 2024
Department of Animal Sciences, Washington State University, Pullman, WA 99164, USA; William H. Miner Agricultural Research Institute, Chazy, NY 12921, USA. Electronic address:
Available literature on the effect of various physical forms of starter feed (PFSF) on calf performance is conflicting. Thus, this study aimed to investigate the effect of the PFSF on feed intake, growth performance, blood metabolites, and the health of dairy calves. Twenty-four female Holstein calves (5-d-old; 40.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!